ReviewSeminars in liver disease2010
The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease.
Review in Seminars in liver disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 106 citations in OpenAlex.
- Cell-type-specific damage scores reveal kidney and liver disease trajectories in single-cell and spatial transcriptomics.Cell genomics · 2026Article
- Lactobacillus paragasseri LPG-9 reduces placental inflammation in intrahepatic cholestasis of pregnancy by regulating TGR5 in mice.Communications biology · 2026Article
- The functions of gut microbiota-mediated bile acid metabolism in intestinal immunity.Journal of advanced research · 2026Review
- The impact of hypothyroidism on the risk of intrahepatic cholestasis of pregnancy: a large-scale study based on pregnant women with hypothyroidism in Shanghai, China.Journal of global health · 2026Article
- Review
- Vincamine alleviates intrahepatic cholestasis in rats through modulation of NF-kB/PDGF/klf6/PPARγ and PI3K/Akt pathways.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Novel Models for Assessing and Pathophysiology of Hepatic Ischemia-Reperfusion Injury Mechanisms.Medicina (Kaunas, Lithuania) · 2024Review
- Structural basis of bile salt extrusion and small-molecule inhibition in human BSEP.Nature communications · 2023Article
- [One case of benign recurrent intrahepatic cholestasis type 2].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023Article
- Protective Effect ofNutrients · 2022Article
- A minimal bile salt excretory pump promoter allows bile acid-driven physiological regulation of transgene expression from a gene therapy vector.Cell & bioscience · 2022Article
- Gene Therapy for Acquired and Genetic Cholestasis.Biomedicines · 2022Review
- Mechanism and Active Components of Qingre Lidan Tablets Alleviate Intrahepatic Cholestasis by Activating the FarnesoidEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Case report: Osteo-oto-hepato-enteric syndrome caused by UNC45A deficiency.Frontiers in genetics · 2022Article
- Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.Acta pharmaceutica Sinica. B · 2021Review
- Hepatic drug-metabolizing enzymes and drug transporters in Wilson's disease patients with liver failure.Pharmacological reports : PR · 2021Article
- The Bile Salt Export Pump: Molecular Structure, Study Models and Small-Molecule Drugs for the Treatment of Inherited BSEP Deficiencies.International journal of molecular sciences · 2021Review
- Current Models for Predicting Drug-induced Cholestasis: The Role of Hepatobiliary Transport System.Iranian journal of pharmaceutical research : IJPR · 2021Review
- Two Novel Pathogenic Variants ofFrontiers in cell and developmental biology · 2021Article
- Equine Drug Transporters: A Mini-Review and Veterinary Perspective.Pharmaceutics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The primary transporter responsible for bile salt secretion is the bile salt export pump (BSEP, ABCB11), a member of the ATP-binding cassette (ABC) superfamily, which is located at the bile canalicular apical domain of hepatocytes. In humans, BSEP deficiency results in several different genetic forms of cholestasis, which include progressive familial intrahepatic cholestasis type 2 (PFIC2), benign recurrent intrahepatic cholestasis type 2 (BRIC2), as well as other acquired forms of cholestasis such as drug-induced cholestasis (DIC) and intrahepatic cholestasis of pregnancy (ICP). Because bile salts play a pivotal role in a wide range of physiologic and pathophysiologic processes, regulation of BSEP expression has been a subject of intense research. The authors briefly describe the molecular characteristics of BSEP and then summarize what is known about its role in the pathogenesis of genetic and acquired cholestatic disorders, emphasizing experimental observations from animal models and cell culture in vitro systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.